Insulin Resistance Syndrome Clinical Trial
Official title:
A Multicenter, Open-label, Single-arm, Extension Study With Regard to the Safety and Efficacy of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-02)
A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.
To determine the safety and efficacy of oral administration of empagliflozin 10 mg or 25 mg once daily for 28 weeks (52 weeks of the EMPIRE-01 study) in subjects who participated in the EMPIRE-01 study, which was conducted on refractory diabetes mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes mellitus) in a multicenter, open-label, single-arm, extension study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04028895 -
Diagnostic Interest of the IRAP Protein (Insulin Regulated Amino Peptidase) in Insulin Resistance
|
N/A | |
| Active, not recruiting |
NCT04018365 -
A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
|
Phase 3 | |
| Completed |
NCT03011775 -
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
|
Phase 4 | |
| Completed |
NCT03716336 -
Aerobic and Strength Training With Caloric Restriction on Insulin Resistance in Obese Premenopausal Women
|
N/A | |
| Completed |
NCT03741686 -
Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome
|
Phase 2 | |
| Recruiting |
NCT04128969 -
Causal Mechanisms in Adolescent Arterial Stiffness
|
Phase 2 |